Mark Clements Joins Glooko as Chief Medical and Strategy Officer

Glooko has awarded its chief medical officer (CMO) a full-time role.

Mark Clements, M.D., Ph.D., has been the company’s fractional CMO since 2016 and now steps into an expanded position (chief medical and strategy officer) designed to strategically integrate Glooko’s clinical vision, product roadmap, and data solutions to accelerate growth and innovation.

“Dr. Clements’ expertise as an endocrinologist, coupled with his deep experience in diabetes digital health, remote patient monitoring, data integration, AI and machine learning, and clinical trial design, positions him to align clinical insights directly with Glooko’s product and service offerings,” Glooko CEO Mike Alvarez said. “We are thrilled to have him in this expanded leadership role that will ensure Glooko continues to enhance health outcomes for people with diabetes, drive healthcare efficiencies, and solidify our market leadership through innovation grounded in clinical insight.”

In addition to his CMO role at Glooko, Dr. Clements most recently served as professor of Pediatrics at the University of Missouri-Kansas City (UMKC) School of Medicine, where he held the Endowed Chair in Endocrinology and Diabetes. At UMKC, Dr. Clements also was medical director of the Pediatric Clinical Research Unit and the Diabetes Research Program and also was co-principal investigator of the TrialNet Clinical Center and data science lead for the Type 1 Diabetes Exchange-Quality Improvement (T1DX-QI) initiative.

“As a long-time advisor to Glooko and an active user of the platform in my clinical practice, I’ve witnessed firsthand how Glooko helps clinical teams consistently deliver measurable improvements in diabetes care outcomes,” Dr. Clements stated. “As we look to the future, precision engagement and population health insights will be key focuses of the company and our platform. We are investing in making it easier for healthcare providers to connect people with diabetes to the Glooko platform, reducing clinical staff burden, optimizing clinician time, helping them stay at the top of their scope of practice, and personalizing interventions. This is a pivotal moment for our company and for diabetes care delivery overall, and I am confident Glooko’s technology will continue to improve how diabetes care is delivered.”

Glooko is focused on improving health outcomes for people with diabetes through its personalized, intelligent, connected care platform. The company’s technologies strengthen connections between patients and providers, and drive patient engagement and adherence through digital therapeutics, with more than 4.4 million people worldwide who have used the Glooko platform. By seamlessly integrating with electronic health records (EHRs), providing a unified device ecosystem, and delivering actionable insights, Glooko aims to enhance clinical workflows and improve outcomes for people with diabetes and their care providers.